Immunohistochemistry Market: Latest Trends, Technological Advancements, Driving Factors, and Forecast until 2029
"F. Hoffmann-La Roche AG (Switzerland) stands out as a major player in the global immunohistochemistry (IHC) market. Operating through its Pathology Lab segment within the Diagnostics Division, Roche provides a comprehensive range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit."
The global immunohistochemistry market, valued at US$3.4B in 2023, is forecasted to grow at a 7.2% CAGR, reaching US$3.7B by 2024 and US$5.2B by 2029.
The global Immunohistochemistry Market is valued at an estimated USD 3.4 billion in 2024 and is projected to reach USD 5.2 billion by 2029 at a CAGR of 7.2% during the forecast period. The global Immunohistochemistry (IHC) market is driven by the rising incidence of cancer, which increases the demand for accurate diagnostic tools like IHC tests. Innovations in antibodies and automated equipment have improved the accuracy and efficiency of cancer detection, while the growing adoption of personalized treatment plans presents significant opportunities. However, alternative technologies such as in situ hybridization, NGS, and RNA sequencing pose challenges to IHC market growth. The rise of digital pathology, offering benefits like reduced turnaround times and improved workflow, further supports market expansion. Nevertheless, the lack of standardization in IHC products limits growth, though ongoing efforts to address this issue are underway. Companion diagnostics, which tailor treatments to individual patients, also present opportunities for market growth. Despite competition from alternative methods, the IHC market continues to grow, with significant contributions from major players like F. Hoffmann-La Roche, Danaher Corporation, and Agilent Technologies. The diagnostic applications segment holds the largest market share, driven by the increasing need for accurate disease diagnosis, while antibodies remain the most significant product segment. Hospitals and diagnostic laboratories are the primary end users, with North America experiencing notable growth due to advanced diagnostic infrastructure and high disease prevalence.
Download PDF Brochure:
Browse in-depth TOC on " Immunohistochemistry Market"
666 - Tables
63 - Figures
489 - Pages
F. Hoffmann-La Roche AG: Leading Innovator in Immunohistochemistry
F. Hoffmann-La Roche AG (Switzerland) stands out as a major player in the global immunohistochemistry (IHC) market. Operating through its Pathology Lab segment within the Diagnostics Division, Roche provides a comprehensive range of IHC products, including the BenchMark ULTRA IHC/ISH System and the OptiView DAB IHC Detection Kit. The company has reinforced its market position with the launch of new and improved products, such as the BenchMark ULTRA PLUS system, the VENTANA DP 600 slide scanner, the Elecsys anti-p53 Immunoassay, and the VENTANA ALK (D5F3) CDx Assay. Roche's global reach spans Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.
Danaher Corporation: Pioneering Solutions in Immunohistochemistry
Danaher Corporation (US) excels in the IHC market through its subsidiary Leica Biosystems. This division, part of the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments, offers a wide array of chemical and immuno-staining instruments, reagents, and consumables. Danaher's market leadership is attributed to its extensive customer base, advanced technology, significant R&D investments—amounting to USD 1.50 billion in 2023—and collaborations with research institutions and clinicians worldwide. Notable developments include a partnership with Navinci for advanced cancer research and the acquisition of Cell IDx, Inc., enhancing Danaher's competitive edge in the IHC market.
Agilent Technologies, Inc.: Key Contributor to IHC Diagnostics
Agilent Technologies, Inc. (US) is a significant player in the IHC market, focusing on cancer diagnostics and anatomic pathology workflows through its Pathology Solutions segment. The company expanded its offerings with partnerships like the one with Incyte for companion diagnostic solutions and with Akoya Biosciences for chromogenic and immunofluorescent multiplex assays. Agilent is also broadening its global footprint with a new Center for Excellence in India and maintains a strong presence in regions including the US, UK, Australia, China, Germany, and Japan, among others.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939
Product Segment: Antibodies Drive Immunohistochemistry Market Growth
The immunohistochemistry (IHC) market is categorized into antibodies, reagents, equipment, and kits. In 2023, antibodies dominated the market, driven by advancements in immunohistochemistry that boost R&D activities for various antibodies. The high demand for primary antibodies, which are essential for IHC protocols and widely used in diagnostic and research applications, supports this segment. Additionally, the growth is fueled by increasing adoption of targeted immunotherapy, heightened awareness of healthcare diagnostics, rising approval rates for therapeutic antibodies, and increased R&D spending by pharmaceutical and biotechnology companies.
Application Segment: Research Applications Contribute Significantly
The IHC market is segmented by application into diagnostic, research, and forensic uses. The research application segment held the second-largest share in 2023. High-throughput automated IHC platforms are utilized in research to ensure consistent staining across slides, crucial for studying drug effects on tissues at the molecular level. IHC products are also vital for identifying drug-induced toxic effects and studying embryonic development, including stem cell differentiation. These factors make IHC techniques essential in developmental studies, stem cell research, and drug testing, thereby contributing to the segment's significant market share.
End-User Segment: Academic and Contract Research Organizations Lead
The IHC market is divided by end users into hospitals & diagnostic laboratories, academic & contract research organizations (CROs), and other entities such as pharmaceutical & biotechnology companies and forensic laboratories. In 2023, academic & CROs represented the second-largest segment. IHC techniques are extensively used for identifying and validating pharmaceutical targets, analyzing tumor-stroma-immune cell interactions, and categorizing patients in clinical trials. The growing demand for personalized cancer treatments, increased application of IHC in drug development, and rising investments in life sciences research drive this segment's expansion.
Regional Insights: North America Dominates the Market
The IHC market is segmented by region into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America led the market in 2023, supported by ongoing economic development, rising healthcare expenditure, and improved access to advanced cancer screening technologies. The region benefits from favorable reimbursement policies for pathology diagnostic tests and high-quality healthcare infrastructure, which further drives the growth of the IHC market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
an hour ago
- Japan Forward
China Backs Students to Influence Japan's Research and Academia
In the United States, concerns about Chinese influence on university campuses have escalated. US authorities have scrutinized institutions like Harvard for accepting large donations from entities linked to the Chinese government, and have arrested researchers with ties to China for concealing affiliations with its military. The FBI has repeatedly warned that the Chinese Communist Party (CCP) is systematically targeting American universities to acquire cutting-edge technology and sensitive research. Washington is tightening oversight on foreign scholars and funding, and Japan is now facing a similar dilemma, yet seems far less prepared. Japan is ramping up support for foreign doctoral students, offering up to ¥2.9 million JPY ($20,040 USD) per year. However, one question looms large: Who exactly is benefiting? According to university professor Rui Sasaki, the answer is increasingly "Chinese students," and he argues that's a dangerous trend Japan can no longer ignore. "Over 40% of these government-supported doctoral students are Chinese," Sasaki explained in a recent interview with JAPAN Forward. "Meanwhile, Japanese students are being left behind. It's both unfair and risky." University of Tokyo's Akamon Gate Sasaki points to the swelling ranks of Chinese students at top universities such as the University of Tokyo, Kyoto University, and Waseda. What may seem like a benign form of international exchange, he warns, actually carries national security implications. "China isn't a G7 country," he said. "It's a dictatorship. We must face that reality." At the center of his concern is the CSC, the China Scholarship Council. Thousands of Chinese students abroad, including in Japan, are funded under this program. But there's a catch: recipients must sign secret contracts pledging loyalty to the Chinese government. "Their families are restricted from leaving China. Embassies and consulates monitor them and they must submit regular reports," Sasaki said. "If the Chinese state demands something, like sensitive data, they cannot refuse." This dynamic poses a serious national security risk, Sasaki warns, particularly in research-intensive fields like science and engineering. "In Tokushima, authorities arrested a Chinese researcher for stealing data. There are likely more cases that go unreported," he noted. The concern isn't abstract. Other democracies have already sounded the alarm. Sweden, Germany, and the Netherlands have investigated CSC-funded students. Some were later linked to the People's Liberation Army or Chinese state security agencies. So why hasn't Japan taken similar precautions? "Japan has no real counterintelligence infrastructure," Sasaki lamented. "Even if you suspect espionage, the legal framework doesn't allow wiretapping in economic or national security cases. The only tools we have are for terrorism or drug crimes." But the risk doesn't stop at individual espionage. Sasaki says Japan's academic institutions are slowly being infiltrated from within. Some CSC-funded students stay on after graduation and work their way up the academic ladder. "They become associate professors or even full professors at Japanese universities," he said. "Then they begin teaching Chinese-style history to Japanese students." Sasaki also draws attention to Confucius Institutes, Chinese government-backed cultural and language centers operating worldwide, often housed within universities. While many Western countries have shuttered these institutions, citing concerns over propaganda and surveillance, Japan still plays host to several. "Waseda University still has one," Sasaki said. "When Hu Jintao or Jiang Zemin visited, the venues filled with Chinese nationals. Just from that scene, you'd think the place was already occupied." Confucius Institute Headquarters in Beijing. (© Kyodo) He warns that this isn't simply about culture — it's part of the CCP's "United Front" strategy, which aims to subtly expand influence through overseas Chinese communities, student associations, and academics. "A lot of Chinese people probably don't even realize they're being used. They're not all spies in the strict sense. But they are being used," he explained. The issue is further complicated by what Sasaki sees as Japan's naivete. "We're still clinging to the idea that more exchange automatically means more peace," he said. "But real internationalization isn't about open borders for everyone. It's about mutual respect and clear rules." He contrasts this with what he calls "globalist delusion" — the belief that authoritarian states will liberalize through engagement alone. "After the Tiananmen massacre, the West imposed sanctions. But Japan broke ranks first, sending the Emperor to China. We thought they'd democratize if we were kind. Instead, we helped them entrench their regime." While Sasaki's warnings may seem alarmist to some, they are part of a growing body of concern shared by intelligence officials, academics, and journalists in liberal democracies worldwide. What sets Japan apart, he says, is how little public awareness exists. "We're not even having the conversation," he said. Even now, he fears Japan is ill-prepared for the future. "People think peace is the default. But peace is something you have to defend. 'When did Noah build the Ark?'" he asks, referencing the film Spy Game . "Before the rain." Author: Daniel Manning
Cision Canada
3 hours ago
- Cision Canada
Nuveen Australian Real Estate Debt Strategy Reaches A$650 Million with CPP Investments Commitment
SYDNEY, /CNW/ - Nuveen, one of the largest asset managers globally with over US$1.3 trillion AUM*, has reached second close of its commingled Australian commercial real estate debt strategy with commitments of over A$650 million. Canada Pension Plan Investment Board (CPP Investments), through its subsidiary CPPIB Credit Investments Inc., invested A$300 million, joining Teachers Insurance and Annuity Association of America (TIAA) and Temasek as strategic partners of Nuveen for this strategy. Total AUM are expected to exceed A$1 billion including capital approved for co-investments. The strategy is already more than 40% deployed via committed loan investments focusing on institutional senior and junior loans secured by prime real estate in Australia. Preferred sectors for the strategy are industrial / logistics and residential, with a selective approach to retail, office and alternatives across major cities in Australia. The strategy leverages both Nuveen Real Estate's global debt platform, which currently has over 55 dedicated specialists, and the team of more than 60 at Nuveen Real Estate in Asia. The strategy is led by Dugald Marr, Nuveen's Head of Debt Australia and New Zealand, and the support of an experienced team with a long track record of originating and structuring high-quality loan investments in this market. Investments are also aligned to Nuveen Real Estate's comprehensive responsible investment processes and ESG factor analysis. This includes waste reduction and energy consumption, climate risk analysis and social aspects with the ability to structure Green Loans or Sustainable Linked Loans where applicable to incentivise ESG targets on behalf of clients. The investment comes at a time when Australian commercial real estate debt offers the potential for a compelling blend of stability, attractive yields, and strong collateral protection, all of which are increasingly important to investors concerned about global volatility. Australia's mature market, supported by robust economic foundations, strict regulatory requirements for banks and the need for more alternative capital sources provides a good foundation for long-term investment in this space. The strategy will continue to focus on repeat institutional borrowers, conservative lending parameters and prime assets in sectors that benefit most from Australia's high population growth and limited supply. Andrew Kleinig, Head of Australia and the Global Client Group for South East Asia at Nuveen, said: "This is another milestone for the strategy. With CPP Investments' commitment, we will continue our focus on strategic, in-depth partnerships with the highest calibre of investors. We are excited to work with a like-minded partner who also shares a high conviction on the asset class. CPP Investments has provided significant value-add as a strategic investor, ensuring long-term success and growth of the partnership. It showcases Nuveen's pedigree in real estate investment and our ability to bring regionally tailored solutions across both equity and debt platforms. We believe Nuveen's offering across real assets more broadly is well-positioned to help clients across Asia navigate volatility alongside managing their responsible investment goals." Raymond Chan, Managing Director & Head of APAC Credit at CPP Investments, said: "Australia is one of our key markets in Asia Pacific and this transaction marks an important milestone for our credit strategy in the region. The investment builds upon our extensive market research and insights from our successful investments in Australia. Leveraging Nuveen's strong local network and capabilities, this partnership enables us to tap into attractive real estate debt investments in Australia and further augment our credit program in the region. These opportunities offer stability and attractive yields amid global volatility, contributing to long-term returns for the CPP Fund." *Top 20 largest global asset manager based on Pensions & Investments, 12 Jun 2023. Rankings based on total worldwide assets as of 31 Dec 2022 reported by each responding asset manager, with 434 firms responding; updated annually. TIAA is the parent company of Nuveen. About Nuveen Nuveen, the investment manager of TIAA, offers a comprehensive range of outcome-focused investment solutions designed to secure the long-term financial goals of institutional and individual investors. Nuveen has $1.3 trillion in assets under management as of 30 September 2024 and operations in 27 countries. Its investment specialists offer deep expertise across a comprehensive range of traditional and alternative investments through a wide array of vehicles and customized strategies. For more information, please visit Nuveen Real Estate is one of the largest investment managers in the world with US$142 billion of assets under management. Managing a suite of funds and mandates, across both public and private investments, and spanning both debt and equity across diverse geographies and investment styles, we provide access to every aspect of real estate investing. With over 90 years of real estate investing experience and more than 770 employees* located across 30+ cities throughout the United States, Europe and Asia Pacific, the platform offers global reach with deep sector expertise, providing investors access to high quality investments across the private real estate investment landscape. For further information, please visit us at *Includes 360+ real estate investment professionals, supported by a further 411 Nuveen employees. Source: Nuveen, 31 March 2025. About CPP Investments Canada Pension Plan Investment Board (CPP Investments™) is a professional investment management organization that manages the Fund in the best interest of the more than 22 million contributors and beneficiaries of the Canada Pension Plan. In order to build diversified portfolios of assets, investments are made around the world in public equities, private equities, real estate, infrastructure and fixed income. Headquartered in Toronto, with offices in Hong Kong, London, Mumbai, New York City, San Francisco, São Paulo and Sydney, CPP Investments is governed and managed independently of the Canada Pension Plan and at arm's length from governments. At March 31, 2025, the Fund totalled C$714.4 billion. For more information, please visit or follow us on LinkedIn, Instagram or on X @CPPInvestments.
Cision Canada
4 hours ago
- Cision Canada
Petro-Victory Energy Corp. Announces Short Term Loans
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS/ DALLAS, June 11, 2025 /CNW/ - Petro-Victory Energy Corp. (TSXV: VRY) (" Petro-Victory" or the " Company") announces that it has borrowed an aggregate of US$350,000 (the " Loans") and issued unsecured promissory notes to Thomas Cooper, a director of the Company, and to an arm's length third party (collectively, the " Lenders"). The Loans have a term of one year and bear interest at an annual rate of 14% per annum until maturity and 18% per annum thereafter. The Lenders will be issued an aggregate of 685,350 bonus warrants (the " Warrants") in connection with the Loans, with each Warrant being exercisable at CAD$0.70 per common share on or before June 2, 2026. The Loans and issuance of Warrants remain subject to TSX Venture Exchange (" TSXV") final acceptance. The Loan from Thomas Cooper in the aggregate amount of US$175,000 and the issuance of 342,675 Warrants in connection therewith each constituted a "related party transaction" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") as Mr. Copper is a related party (as defined in MI 61-101) of the Company. The Company relied on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in Sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party matters, as the Company is listed on the TSXV and neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the related parties, exceeded 25% of the Company's market capitalization (as determined under MI 61-101). About Petro-Victory Energy Corp. Petro-Victory Energy Corp. is an oil and gas company engaged in the acquisition, development, and production of crude oil and natural gas in Brazil. The total portfolio under management includes 49 concession contracts with 276,755 acres, net to Petro-Victory plus an additional 6 concessions and 19,074 acres owned jointly with BlueOak. Through disciplined investments in high-impact, low-risk assets, Petro-Victory is focused on delivering sustainable shareholder value. The Company's common shares trade on the TSX Venture Exchange under the ticker symbol VRY. Cautionary Note Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States unless an exemption from such registration is available. In the interest of providing Petro-Victory's shareholders and potential investors with information regarding Petro-Victory's future plans and operations, certain statements in this press release are "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation (collectively, " forward-looking statements"). In some cases, forward-looking statements can be identified by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "intend," "may," "objective," "ongoing," "outlook," "potential," "project," "plan," "should," "target," "would," "will" or similar words suggesting future outcomes, events or performance. The forward-looking statements contained in this press release speak only as of the date thereof and are expressly qualified by this cautionary statement. Specifically, this press release contains forward-looking statements relating to, but not limited to, TSXV approval for the Loan and Warrants. These forward-looking statements are based on certain key assumptions regarding, among other things, the receipt of TSXV approval for the Loan and Warrants. Readers are cautioned that such assumptions, although considered reasonable by Petro-Victory at the time of preparation, may prove to be incorrect. Actual results achieved will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The above summary of assumptions and risks related to forward-looking statements in this press release has been provided in order to provide shareholders and potential investors with a more complete perspective on Petro-Victory's current and future operations and such information may not be appropriate for other purposes. There is no representation by Petro-Victory that actual results achieved will be the same in whole or in part as those referenced in the forward-looking statements and Petro-Victory does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law. SOURCE Petro-Victory Energy Corp.
